[Use of anti-B-cell therapy in case of antisynthetase syndrome as the severest subtype of polymyositis/dermatomyositis].

Abstract

Antisynthetase syndrome encompassing a symptom complex with severe interstitial lung disease is the severest subtype of polymyositis and dermatomyositis. The characteristic feature of antisynthetase syndrome is the insufficient efficiency of traditional therapy with glucocorticosteroids and cytostatics, which determines the prognosis of the disease and the need for new therapeutic approaches to treating these patients.

• Authors: O A Antelava, A N Khelkovskaia-Sergeeva, G M Tarasova, N Iu Nikishina, N E Lopatina, S G Pal'shina, T P Fedina, E G Sazhina
• Journal: Terapevticheskii arkhiv (Ter Arkh) Vol. 86 Issue 5 Pg. 109-15 ( 2014) ISSN: 0040-3660 [Print] Russia (Federation)
• PMID: 25026812 (Publication Type: English Abstract, Journal Article)

Chemical References

• Antibodies, Monoclonal, Murine-Derived
• Antigens, CD20
• Immunologic Factors
• Rituximab

Topics

• Antibodies, Monoclonal, Murine-Derived (administration & dosage, adverse effects, immunology)
• Antigens, CD20 (analysis)
• Cell- and Tissue-Based Therapy (methods)
• Dermatomyositis (complications, immunology)
• Drug Monitoring
• Humans
• Immunologic Factors (administration & dosage, adverse effects, immunology)
• Lung Diseases, Interstitial (etiology, physiopathology)
• Monitoring, Immunologic
• Myositis (etiology, immunology, physiopathology, therapy)
• Randomized Controlled Trials as Topic
• Rituximab
• Treatment Outcome